Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note published on Monday morning,RTT News reports. The brokerage currently has a $23.00 target price on the stock. A number of other research firms also recently weighed in on YMAB. Brookline Capital Management began coverage on Y-mAbs Therapeutics […]
Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note published on Monday morning,RTT News reports. The brokerage currently has a $23.00 target price on the stock. A number of other research firms also recently weighed in on YMAB. Brookline Capital Management began coverage on Y-mAbs Therapeutics […]
